Effect of vaccination route and composition of DNA vaccine on the induction of protective immunity against pseudorabies infection in pigs

Rooij, E.M.A. van; Haagmans, Bart L.; Visser, Y.E. de; Bruin, M.G.M. de; Boersma, W.J.A.; Bianchi, A.T.J.

doi:10.1016/s0165-2427(98)00186-x

Cited by 72 publications

(37 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Perhaps the most promising vaccine technology currently being tested is the administration of naked DNA encoding for antigens known to have the potential to induce protective immunity. So far, the administration of plasmids capable of expressing either gC or gD have been shown to induce immunity and in several cases protection in pigs against Aujeszky's disease [15,16,33,54]. A critical challenge remaining for this technology is the demonstration that the effectiveness of DNA vaccination can be made to emulate the level of protective immunity induced by conventional MLV vaccines.…”

Section: Adv and Novel Vaccine Designmentioning

confidence: 99%

Aujeszky's disease virus: opportunities and challenges

Zuckermann¹

2000

Vet. Res.

View full text Add to dashboard Cite

-Since its description in 1902, Aujeszky's disease (AD) has become one of the most thoroughly examined viral diseases of swine. The causative agent, Aujeszky's disease virus (ADV), is a neurotropic alphaherpesvirus that produces fatal encephalitis in newborn pigs and a milder syndrome in older animals. In several instances this virus has been used as a test case to examine novel vaccine concepts in swine, including the honor of being the first genetically modified vaccine used in the field. Furthermore, the examination of the immune response to infection or vaccination with this virus has revealed important information about the function of the porcine immune system, including evidence on the existence of a dichotomy between the humoral and cellular immune response in swine. This review presents a summary of research where ADV has been a valuable tool for the development of novel vaccines and has provided information to better understand the immune response of swine to infectious agents. Aujeszky's disease virus / immunity / vaccine / T cells / pigRésumé -Virus de la maladie d'Aujeszky : perspectives et défis. Depuis sa description en 1902, la maladie d'Aujeszky est devenue l'une des maladies virales du porc les plus minutieusement étu-diées. L'agent pathogène responsable de la maladie, le virus de la maladie d'Aujeszky, est un alphaherpesvirus neurotrope qui provoque des encéphalites fatales chez le porc nouveau-né, et un syndrome plus modéré chez les animaux plus âgés. À plusieurs reprises, ce virus a été utilisé expérimentalement pour l'étude de nouveaux concepts vaccinaux chez le porc, et a eu l'honneur d'être le premier vaccin génétiquement modifié utilisé sur le terrain. De plus, l'examen de la réponse immunitaire à l'infection ou à la vaccination par ce virus a révélé des informations importantes concernant le fonctionnement du système immunitaire porcin. En particulier, des preuves de l'existence d'une dichotomie entre les réponses immunitaires humorale et cellulaire chez le porc ont été mises en évidence. Cet article de synthèse résume la recherche pour laquelle ADV a été un outil précieux pour le déve-loppement de nouveaux vaccins, et a apporté des informations pour une meilleure compréhension de la réponse immunitaire du porc aux agents infectieux. Vet. Res. 31 (2000) 121-131 121 virus de la maladie d'Aujeszky / immunité / vaccin / cellules T / porc

show abstract

Section: Adv and Novel Vaccine Designmentioning

confidence: 99%

Aujeszky's disease virus: opportunities and challenges

Zuckermann¹

2000

Vet. Res.

View full text Add to dashboard Cite

show abstract

“…swine, cattle and sheep remains a major challenge (Krishnan and Rajendra, 2000). Some studies have showed a variety of ways to boost immune responses by changing the delivery parameters (van Rooij et al, 1998) and improving the transfection efficiency (Braun et al, 1999) or by adding immune modulatory molecules such as: cytokine (e.g. CD154) and costimulatory molecules (van Drunen Littel-van den Hurk et al, 2004).…”

Section: Discussionmentioning

confidence: 99%

Cloning, sequence analysis and expression of ovine CD154 (CD40 ligand)

Olędzka

Kay

et al. 2007

Molecular Immunology

View full text Add to dashboard Cite

The CD154 (CD40 ligand) molecule is a member of the tumor necrosis factor (TNF) family and plays an important role in the interaction between antigen-specific lymphocytes and antigen-presenting cells. In this study, reverse transcription-PCR cloning was used to derive the sequence encoding ovine CD154. Sequence analysis of the cloned CD154 gene showed a similarity of 97, 89 and 88% with the bovine, porcine and human sequences, respectively, at the nucleic acid level. The deduced amino acid sequence for the ovine CD154

show abstract

“…13 DNA vaccine technology also eliminates the need for biocontainment and the risk of exposure to live viral agents. Several modalities have been employed to deliver DNA vaccines, including intramuscular injection using conventional needle and syringe, 3 electroporation, 14 intradermally by the needle-free biojector 15 and epidermally through a gene gun. 16,17 However, one of the concerns regarding DNA vaccines is their limited potency.…”

Section: Introductionmentioning

confidence: 99%

Noncarrier naked antigen-specific DNA vaccine generates potent antigen-specific immunologic responses and antitumor effects

Sun

et al. 2009

Gene Ther

View full text Add to dashboard Cite

Genetic immunization strategies have largely focused on the use of plasmid DNA with a gene gun. However, there remains a clear need to further improve the efficiency, safety, and cost of potential DNA vaccines. The gold particle-coated DNA format delivered through a gene gun is expensive, time and process consuming, and raises aseptic safety concerns. This study aims to determine whether a low-pressured gene gun can deliver noncarrier naked DNA vaccine without any particle coating, and generate similarly strong antigen-specific immunologic responses and potent antitumor effects compared with gold particle-coated DNA vaccine. Our results show that mice vaccinated with noncarrier naked chimeric CRT/E7 DNA lead to dramatic increases in the numbers of E7-specific CD8 + T-cell precursors and markedly raised titers of E7-specific antibodies. Furthermore, noncarrier naked CRT/E7 DNA vaccine generated potent antitumor effects against subcutaneous E7-expressing tumors and pre-established E7-expressing metastatic pulmonary tumors. In addition, mice immunized with noncarrier naked CRT/E7 DNA vaccine had significantly less burning effects on the skin compared with those vaccinated with gold particle-coated CRT/E7 DNA vaccine. We conclude that noncarrier naked CRT/E7 DNA vaccine delivered with a low-pressured gene gun can generate similarly potent immunologic responses and effective antitumor effects has fewer side effects, and is more convenient than conventional gold particle-coated DNA vaccine.

show abstract

Effect of vaccination route and composition of DNA vaccine on the induction of protective immunity against pseudorabies infection in pigs

Cited by 72 publications

References 26 publications

Aujeszky's disease virus: opportunities and challenges

Aujeszky's disease virus: opportunities and challenges

Cloning, sequence analysis and expression of ovine CD154 (CD40 ligand)

Noncarrier naked antigen-specific DNA vaccine generates potent antigen-specific immunologic responses and antitumor effects

Contact Info

Product

Resources

About